Close Menu

NEW YORK ─ Agilent Technologies on Tuesday announced it has obtained clearance from Japan's Ministry of Health, Labour, and Welfare for its GenetiSure Dx Postnatal Assay, bringing comparative genomic hybridization to diagnostic settings in that country.

Santa Clara, California-based Agilent said it anticipates launching the assay in Japan in the first half of 2021.

The test enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.